Clinical trials · Washington, D.C., DC
Cancer clinical trials in Washington, D.C.
We’re tracking 953 recruiting cancer studies with a site in or near Washington, D.C. — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Washington, D.C.
- NCT07174583RecruitingPhase 1/Phase 2
Study of IDE849 for DLL3-positive cancers like SCLC
This trial tests a new drug called IDE849 for cancers that make a protein called DLL3, including small cell lung cancer and some neuroendocrine tumors. It is for people whose cancer has progressed after standard treatments, and may be given alone or combined with other drugs like durvalumab or IDE161.
Fairfax, VirginiaAges 18 years+ - NCT07217171RecruitingPhase 1
Study of EVOLVE104 for advanced bladder and squamous cell cancers
This trial tests an experimental drug called EVOLVE104 for people with advanced bladder cancer or certain types of squamous cell cancers. It aims to see if the drug is safe and if it can help shrink tumors.
Fairfax, VirginiaAges 18 years+ - NCT06586957RecruitingPhase 1
Study of NKT3964 for advanced solid tumors
This trial tests an experimental drug called NKT3964 for people with certain advanced cancers that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
Fairfax, VirginiaAges 19 years+ - NCT07397338RecruitingPhase 1/Phase 2
RAS inhibitors with ivonescimab for solid tumors
This trial tests new drugs called RAS(ON) inhibitors combined with ivonescimab for people with solid tumors that have a RAS mutation. It aims to see if this combination can shrink tumors or slow their growth.
Fairfax, VirginiaAges 18 years+ - NCT07155174RecruitingPhase 2
Testing new drug combo for first-line extensive small cell lung cancer
This trial tests a new combination treatment (ABBV-706 plus atezolizumab) as a first option for people with extensive stage small cell lung cancer. It compares this new approach to the usual standard treatment, aiming to see if it works better and has fewer side effects.
Fairfax, VirginiaAges 18 years+ - NCT06568939RecruitingPhase 2
Study of telisotuzumab vedotin for non-squamous lung cancer
This trial tests a drug called telisotuzumab vedotin (ABBV-399) given through a vein to people with a specific type of advanced lung cancer (non-squamous non-small cell lung cancer) that has a high level of a protein called c-Met. The study aims to see how the drug affects the body and helps control the cancer.
Fairfax, VirginiaAges 18 years+ - NCT06638307RecruitingPhase 1
Study of new drug MEN2312 for advanced breast cancer with specific genetic changes
This trial tests a new drug, MEN2312, for people with advanced breast cancer that has specific genetic changes in PIK3CA, AKT1, or PTEN. It's for those who have already tried certain hormone therapies and a CDK4/6 inhibitor combination, and the cancer has continued to grow.
Fairfax, VirginiaAges 18 years+ - NCT05768139RecruitingPhase 1/Phase 2
Testing a new targeted drug for advanced solid tumors with PI3Kα mutation
This trial tests tersolisib, a new targeted medicine, in adults with advanced or hard-to-remove solid cancers. It focuses on tumors that have a specific genetic change (PI3Kα mutation) to see how well the treatment works and what side effects it causes.
Fairfax, VirginiaAges 18 years+ - NCT07300241RecruitingPhase 1
Study of NEO-811 for advanced kidney cancer
This trial tests a new drug called NEO-811 for people with advanced clear cell kidney cancer that has spread and can't be removed with surgery. The goal is to see if it helps when other treatments have stopped working or aren't an option.
Fairfax, VirginiaAges 18 years+ - NCT07094204RecruitingPhase 1
Study of ASP5834 for advanced solid tumors with KRAS changes
This study tests a new drug (ASP5834) for people with advanced solid tumors that have changes in the KRAS gene. The study looks for a safe and effective dose, and may help you if your standard treatments have stopped working.
Fairfax, VirginiaAges 18 years+ - NCT06707610RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests a new drug called ALK202 for people with advanced solid tumors that have not responded to other treatments. The study aims to see if the drug is safe and to find the best dose.
Fairfax, VirginiaAges 18–75 - NCT06445062RecruitingPhase 1/Phase 2
RAS-targeting drugs for gastrointestinal cancers
This trial tests new drugs that target a specific genetic change (RAS) in gastrointestinal cancers like pancreatic and colorectal cancer. The goal is to see if these drugs can shrink or slow down the cancer.
Fairfax, VirginiaAges 18 years+ - NCT00969111Recruiting
Radiation after prostate surgery for prostate cancer without nodal spread
This trial looks at radiation therapy given after prostate surgery (or if needed later) for prostate cancer where lymph nodes were not involved. It may help patients whose PSA rises or who need additional treatment to reduce the chance the cancer comes back.
Fairfax, VirginiaAges 18 years+ - NCT05208762RecruitingPhase 1
PD-L1 antibody drug study for advanced lung and head/neck cancers
This Phase 1 trial tests a new experimental drug (PF-08046054/SGN-PDL1V) in people with advanced solid tumors that have not responded to standard treatment or can’t use it. It is designed to see how the drug works and how safe it is, with a focus on tumors that have PD-L1 seen on prior lab testing.
Fairfax, VirginiaAges 18 years+ - NCT06103864RecruitingPhase 3
Study of Dato-DXd with or without durvalumab for advanced triple-negative breast cancer
This trial is testing whether a new drug combination (Dato-DXd with or without durvalumab) works better than standard chemotherapy plus pembrolizumab for people with a certain type of advanced triple-negative breast cancer that has a protein called PD-L1. The study aims to find a more effective treatment option for this specific group.
Fairfax, VirginiaAges 18 years+ - NCT07023289RecruitingPhase 2
Study of Telisotuzumab Adizutecan for ctDNA-Positive Colorectal Cancer
This trial tests a new drug, Telisotuzumab Adizutecan, given through a vein (infusion) alone or with standard treatments for people with colorectal cancer who have no visible tumors on scans but still have cancer DNA (ctDNA) in their blood after surgery and chemotherapy.
Fairfax, VirginiaAges 18 years+ - NCT07562152RecruitingPhase 3
Atebimetinib Plus Gemcitabine/Nab-Paclitaxel for New Pancreatic Cancer
This trial tests a combination of three drugs—atebimetinib (a new targeted therapy), gemcitabine, and nab-paclitaxel (two standard chemotherapy drugs)—as a first treatment for pancreatic cancer that has spread beyond the pancreas. The goal is to see if adding atebimetinib helps patients live longer and feel better.
Fairfax, VirginiaAges 18 years+ - NCT07745361RecruitingPhase 2
Study of MRT-2359 with apalutamide for prostate cancer
This trial tests a new oral drug, MRT-2359, combined with apalutamide (a standard hormone therapy) in men with a specific type of prostate cancer that has stopped responding to hormone treatment. The goal is to see if the combination can slow or stop the cancer's growth.
Fairfax, VirginiaAges 18 years+ - NCT07046923RecruitingPhase 1
A study of LY4175408 for advanced cancer
This trial tests a new targeted drug (LY4175408) for people with certain advanced solid tumors (lung, endometrial, or triple negative breast cancer) who have already tried standard treatments. The goal is to see if the drug is safe and effective.
Fairfax, VirginiaAges 18 years+ - NCT06785636RecruitingPhase 1/Phase 2
New drug combination for advanced prostate cancer
This study tests a new drug (pocenbrodib) alone or combined with another hormone therapy (darolutamide) for men with advanced prostate cancer that has spread. It is for those who have already tried Pluvicto and one other hormone therapy, but not yet chemotherapy.
Fairfax, VirginiaAges 18 years+ - NCT06293898RecruitingPhase 1
Study of BL-M07D1 for HER2-positive solid tumors
This trial tests a new drug, BL-M07D1, for people with advanced solid tumors that have a protein called HER2. It is for patients who have already tried at least two other standard treatments.
Fairfax, VirginiaAges 18 years+ - NCT06303505RecruitingPhase 1/Phase 2
TUB-040 for advanced ovarian or lung cancer after standard treatments fail
This study tests a new drug called TUB-040 for people with ovarian cancer that has stopped responding to platinum chemotherapy, or with a type of lung cancer that has returned or spread. The drug is designed to target cancer cells and deliver a powerful anti-cancer agent directly to them, potentially slowing the disease.
Fairfax, VirginiaAges 18 years+ - NCT07503808RecruitingPhase 1
IDE034 for advanced solid tumors with B7-H3 or PTK7
This study tests a new drug called IDE034 for people with advanced solid tumors that have certain markers (B7-H3 and PTK7). The drug may help by targeting these markers on cancer cells, and the study checks if it is safe and effective.
Fairfax, VirginiaAges 18 years+ - NCT06014658RecruitingPhase 1/Phase 2
Study of MBRC-101 for advanced solid tumors
This trial tests a new drug, MBRC-101, that targets a protein called EphA5 found on some cancer cells. It is for people with advanced solid tumors (like lung, breast, or pancreatic cancer) that have stopped responding to other treatments. The study aims to find a safe dose and see if the drug can shrink tumors.
Fairfax, VirginiaAges 18 years+
Hear when a new Cancer trial opens near Washington, D.C., DC
We’ll email you when one opens near Washington, D.C., DC — at most once a week, no account needed, unsubscribe anytime.
Cancer trials in other cities
Where these studies are running near Washington, D.C.
Institutions with a site for the recruiting cancer studies listed above.
- Virginia Cancer Specialists · 7 studies
- NEXT Oncology · 6 studies
- NEXT Virginia · 5 studies
- Inova Schar Cancer Institute · 3 studies
- Johns Hopkins Hospital
- Johns Hopkins Medicine
- Johns Hopkins University
- Maryland Oncology
What taking part in a cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting cancer studies in District of Columbia.
Common questions
- Are there cancer clinical trials near Washington, D.C.?
- Yes. We're currently tracking 953 recruiting cancer studies with a site near Washington, D.C., each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cancer study near Washington, D.C.?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Washington, D.C. to take part?
- Not necessarily. These studies have a site near Washington, D.C., but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cancer studies open near Washington, D.C. regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.